Non-Opioid Pain Relief: New Molecule Offers Weeks of Relief
Groundbreaking research unveils a new molecule offering weeks of pain relief for chronic sufferers. This targeted non-opioid approach, developed through preclinical studies, could revolutionize pain management, providing lasting relief with a single injection. The molecule cleverly disrupts pain signals by targeting the Magi-1 protein, a critical element in pain transmission.Unlike conventional anesthetics, this innovative solution zeroes in on pain fibers, promising a more precise and effective treatment. Scientists have successfully tested this molecule on human neurons, a crucial step towards future clinical use. The research, backed by the National Institutes of Health, offers hope for millions impacted by chronic pain seeking relief from the opioid crisis. News Directory 3 continues to bring you the latest breakthroughs. Toxicity trials are next, with researchers anticipating minimal side effects. discover what’s next for this promising pain solution.
New Molecule Offers Hope for Chronic Pain Sufferers
A novel molecule shows promise as a long-lasting, targeted anesthetic for chronic pain, according to preclinical studies. The non-opioid approach could provide notable relief for millions who struggle to find adequate pain management.
arin Bhattacharjee, professor of pharmacology and toxicology at the University at buffalo’s Jacobs School of Medicine and Biomedical Sciences, described the molecule as acting like a local anesthetic, but with greater precision. Bhattacharjee is also cofounder of Channavix Therapeutics LLC, a startup aiming to commercialize these new pain relievers.
Unlike customary local anesthetics that block all sensation and have short durations,this new molecule specifically targets pain fibers and provides relief for up to three weeks with a single injection. The research, funded by the National Institutes of Health’s HEAL Initiative, appears in the journal Pain.
The molecule hones in on the Magi-1 protein, a key player in pain transmission. Magi-1 interacts with NaV1.8, an ion channel responsible for transmitting pain signals. By targeting this interaction, the new molecule disrupts the pain pathway.
Bhattacharjee explained that the molecule, a lipidated peptide, acts as a “decoy,” preventing NaV1.8 channels from binding to Magi-1. This leads to the degradation of the NaV1.8 channels,effectively blocking pain signals. The lipid modification allows the peptide to anchor within the neuronal membrane, protecting it from degradation and prolonging its effects.
“When this decoy peptide is introduced into pain neurons, it outcompetes NaV1.8 channels binding to Magi-1,” Bhattacharjee said. “The ‘liberated’ NaV1.8 channels are now left exposed as they become targets for degrading enzymes.”
The team confirmed the molecule’s effectiveness in human pain neurons, a crucial step toward potential drug growth.
What’s next
The next step involves toxicity trials. Bhattacharjee anticipates minimal toxicity due to the localized injection method. The team is seeking partners to advance the peptide to clinical trials, offering a potential new avenue for chronic pain treatment and pain relief.